Processing

Please wait...

Settings

Settings

Goto Application

1. WO1989007454 - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LUNG OBSTRUCTIONS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS
1. Pharmaceutical composition for a therapeutic or prophylactic treatment of lung obstructions, characterized in that it, besides inert diluents and expedients consists of a therapeuti ca l-ly active amount of at least one beta adrenergic agonist and a therapeutically active amount of at least one active thyroid hormone .

2. Pharmaceutical composition according to claim 1, characteri-zed in that the ingoing amount of beta adrenergic agonist is reduced with up to 60% in relation to the situation when the agonist is used alone for the same indication.

3. Pharmaceut cal composition according to claim 1, characteri-zed in that the ingoing amount of active thyroid hormone is reduced with up to 60% in relation to the situation when the hoi— mone is used alone.

4. Pharmaceu ical composition according to claims 1 to 3, cha-racterized in that the beta adrenergic agonist is selected from the group consisting of salbutamole, terbutaline, phenoterole, epinephrine, i sop rena I ine, o rci p rena I ine , riniterole and other unspecific and specific beta-2-adr energi c agonists.

5. Pharmaceutical composition according to claims 1 to 3, characterized in that the active thyroid hormone is selected from the group consisting of thyroxine, tr iodothyroni ne, diiodo-thyronine, and other active thyronine analogues.

6. Pharmaceut cal composition according to claims 1 to 5, characterized in that it is present in the shape of an administration form suitable for inhalation.

7. Pharmaceutical composition according to claims 1 to 5, cha-racterized in that it is present in the shape of an injectable so lut ion .

8. Pharmaceutical composition according to claims 1 to 5, characterized in that it is present in the shape of an administration form for peroral use.

9. Pharmaceutical composition according to claims 1 to 8, characterized in that the molar ratio between the ingoing beta adrenergic agonist and the thyroid hormone is 100:1 - 1:1, preferably 10:1 - 1:1.

10. Pharmaceutical composition according to claims 1 to 9, characterized in that the single dose of active components is 1 to 1000 #ug, preferably 10 to 500 .ug, when administered in the form of an inhalation composition.